Bioinformatics Advance Access originally published online on September 6, 2005
Bioinformatics 2005 21(21):3943-3950; doi:10.1093/bioinformatics/bti654
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Computational methods for the design of effective therapies against drug resistant HIV strains
1Department of Mathematics, University of California Berkeley, CA, USA
2Max Planck Institute for Informatics Saarbrücken, Germany
3Center of Advanced European Studies and Research Bonn, Germany
4Max Planck Institute of Molecular Plant Physiology and University of Potsdam Germany
5Institute of Clinical and Molecular Virology, University of Erlangen-Nürnberg Erlangen, Germany
6Medical Laboratory Berlin, Germany
7PZB Aachen, Germany
8Department of Internal Medicine, University of Cologne Germany
9Institute of Virology, University of Cologne Germany
10Department of Gastroenterology, University of Düsseldorf Germany
11Department of Internal Medicine, University of Bonn Germany
12Institute of Medical Microbiology and Immunology, University of Bonn Germany
*To whom correspondence should be addressed.
Summary: The development of drug resistance is a major obstacle to successful treatment of HIV infection. The extraordinary replication dynamics of HIV facilitates its escape from selective pressure exerted by the human immune system and by combination drug therapy. We have developed several computational methods whose combined use can support the design of optimal antiretroviral therapies based on viral genomic data.
Contact: niko{at}math.berkeley.edu
Received on June 8, 2005; revised on July 27, 2005; accepted on August 30, 2005
This article has been cited by other articles:
![]() |
P. Frange, J. Galimand, C. Goujard, C. Deveau, J. Ghosn, C. Rouzioux, L. Meyer, and M.-L. Chaix High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study J. Antimicrob. Chemother., July 1, 2009; 64(1): 135 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Paar, C. Palmetshofer, K. Flieger, M. Geit, R. Kaiser, H. Stekel, and J. Berg Genotypic Antiretroviral Resistance Testing for Human Immunodeficiency Virus Type 1 Integrase Inhibitors by Use of the TruGene Sequencing System J. Clin. Microbiol., December 1, 2008; 46(12): 4087 - 4090. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Deforche, R. Camacho, K. Van Laethem, P. Lemey, A. Rambaut, Y. Moreau, and A.-M. Vandamme Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment Bioinformatics, January 1, 2008; 24(1): 34 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Beerenwinkel and M. Drton A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data Biostat., January 1, 2007; 8(1): 53 - 71. [Abstract] [Full Text] [PDF] |
||||



